Company Profile
SOLIGENIX Stock Price, News & Analysis
- Ticker:
- SNGX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.38 USD (-1.07%)
Close
Last updated: August 6, 2026
11.1M USD
Market cap
Why the stock is moving
The latest monitored company update is “Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Rare-Disease Biopharmaceutical Company
Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs.
HyBryte
HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study was stopped for futility following an interim analysis, creating uncertainty around the program's path forward.
Dusquetide
SGX945, or dusquetide, is an innate-defense regulator that has generated prior clinical data in Behçet's disease. Soligenix is evaluating strategic options, including whether to advance this program.
Future catalysts
SOLIGENIX's catalyst setup now looks most tied to its latest development priorities. What gives this more shape is May 8, 2026 Skip to content soligenix-logo Soligenix Main Menu About Soligenix Show submenu Corporate Overview Scientific Advisory Boards Show submenu Scientific Advisory Board.... That setup makes the next update more important than the headline financials themselves.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SOLIGENIX (SNGX)?
SOLIGENIX (SNGX) most recently closed at 0.38 USD, a -1.07% move versus the previous session.
What is the market cap of SOLIGENIX (SNGX)?
SOLIGENIX currently has a market capitalization of 11.1M USD on BioPharmSignal.
What does SOLIGENIX do?
Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs. HyBryte HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study was stopped for...
On which exchange is SNGX stock listed?
SOLIGENIX (SNGX) is associated with NASDAQ, United States, Biopharma.
What is Rare-Disease?
Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need.
Which conditions is SOLIGENIX targeting with Rare-Disease?
SOLIGENIX is associated with oncology, rare disease based on its company overview and current catalyst commentary.
How does SOLIGENIX describe recent progress with Rare-Disease?
SOLIGENIX's catalyst setup now looks most tied to its latest development priorities. What gives this more shape is May 8, 2026 Skip to content soligenix-logo Soligenix Main Menu About Soligenix Show submenu Corporate Overview Scientific Advisory Boards Show submenu Scientific Advisory Board.... That setup makes the next update more important than the...
What is Biopharmaceutical?
Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need.